Hematologic Malignancies Market: Industry Analysis and Forecast (2021-2027) by Type, Therapy, and Region

Hematologic Malignancies Market size was valued at US$ 3.24 Bn. in 2020 and the total revenue is expected to grow at 4.3% through 2021 to 2027, reaching nearly US$ 4.35 Bn.

Hematologic Malignancies Market Overview:

Cancers of the blood, bone marrow, and lymph nodes are known as hematologic malignancies. Acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML)), myeloma, and lymphoma (Hodgkin's and non-(NHL)) Hodgkin's are all included in this categorization. Last year, hematologic malignancies accounted for 9% of all newly diagnosed cancers in the United States, with lymphomas (particularly NHLs) being more frequent than leukemias and myeloma. Hematologic Malignancies Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report

Hematologic Malignancies Market Dynamics:

The market is likely to be driven by an increase in the prevalence of blood cancer and a greater focus on the development of innovative treatments. Blood cancers are the fifth most prevalent malignancy worldwide and the second main cause of cancer death. Leukemia, lymphoma, and multiple myeloma are the three most prevalent blood malignancies. Every year, more than 300,000 people are diagnosed with leukemia and 400,000 with lymphoma around the world. The oncology category is seeing the most acquisitions and cooperation, with huge pharma companies cooperating. In 2019, there were a lot of collaborations in cancer therapies, which shows how popular this field is. Various organizations and research institutes from all around the world are working to discover new hematologic malignancy medicines. Furthermore, the hematologic malignancies market is predicted to rise due to the development of new regulatory approvals for novel medications for blood cancer. For example, Pfizer announced in 2015 that the FDA has designated inotuzumab (antibody-drug conjugate) as a breakthrough therapy for acute lymphoblastic leukemia.

Hematologic Malignancies Market Segment Analysis:

The Acute lymphocytic leukemia segment is dominating the Type segment of the Hematologic Malignancies Market: Acute lymphocytic leukemia (ALL) is the most common kind of leukemia, accounting for 56% of occurrences in adolescents and 80% of children in the past few years. As of the presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are estimated to be among the biggest revenue-generating oncology medications, leukemia was the largest segment in 2016. Due to a solid product pipeline and planned commercialization, acute myeloid is expected to increase at the quickest rate during the forecast period. The Chemotherapy segment is considered to supplement the growth of the Hematologic Malignancies Market. Chemotherapy, which is the initial line of treatment, was the most popular part in 2016. Chemotherapy is the standard treatment for most types of blood cancer, and depending on the type of cancer, a specific medicine or combination of drugs is utilized. Due to an increase in cancer incidence, demand for chemotherapy medications is expected to rise. Cancer is the second biggest cause of death worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018. Further, Increased frequency of malignancies such as breast Caner, lung cancer, prostate, leukaemia, and lymphoma, as well as an increase in the elderly population and government healthcare spending increase the global market for chemotherapeutic medications. The global market is bolstered by increased expenditure in anti-cancer drug research and development, as well as increased demand for advanced cancer treatments. The worldwide chemotherapy medications market is also expected to benefit from increased awareness about cancer and its treatment, as well as early detection. Hence, this factor is further estimated to lift the growth of the market. Hematologic Malignancies Market

Hematologic Malignancies Market Regional Insights:

North America is estimated to dominate the growth of the Hematologic Malignancies Market. In 2019, North America dominated the hematologic malignancy market, with a market share of approximately 42.3%. The growth of the region is attributed to the presence of key players, developed healthcare infrastructure, and the availability of branded pharmaceuticals. Furthermore, favorable government efforts and an increase in the number of research collaborations are projected to propel the market forward. The extensive proportion of the analyzed market in North America is due to the presence of key companies, a high prevalence of blood cancer patients, developed healthcare infrastructure, and the availability of branded pharmaceuticals. Additionally, favorable government efforts and an increase in the number of research partnerships are likely to boost market expansion. For example, in December 2020, the Leukemia and Lymphoma Society (LLS) announced a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly USD 17 million in research grants to help patients with leukemia, lymphoma, myeloma, and other blood cancers find effective treatment options. The objective of the report is to present a comprehensive analysis of the Hematologic Malignancies Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Hematologic Malignancies Market dynamics, structure by analyzing the market segments and project the Hematologic Malignancies Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Hematologic Malignancies Market make the report investor’s guide.

Hematologic Malignancies Market Scope: Inquire before buying

Hematologic Malignancies Market

Hematologic Malignancies Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Hematologic Malignancies Market Key Player

Glenmark Pharmaceuticals Inc • GlaxoSmithKline • Boehringer Ingelheim International GmbHPfizer, Inc. • F. Hoffmann-LA Roche lt • Sanofi-Aventis • Bristol-Myers Squibb Company • AbbVie, Inc. • Novartis AG • Celgene Corporation • Johnson & Johnson Services, Inc • Takeda Pharmaceutical Company Limited • Sanofi • AstraZeneca • Amgen Inc. • Byer AG

FAQs:

1. What is the Hematologic Malignancies market value in 2020? Ans: Hematologic Malignancies market value in 2020 was estimated as 3.24 Billion USD. 2. What is the Hematologic Malignancies market growth? Ans: The Hematologic Malignancies market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.35 Billion by the end of 2027. 3. Which Type segment is expected to dominate the Hematologic Malignancies market during the forecast period? Ans: Chemotherapy was the largest segment in 2019, as it is the first line of treatment. For most types of blood cancer, chemotherapy is the usual treatment and a particular drug or combination of drugs is used, based on the type of cancer. 4. Who are the key players in the Hematologic Malignancies market? Ans: Some key players operating in the Hematologic Malignancies market include Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi-Aventis; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited. 5. What is the key driving factor for the growth of the Hematologic Malignancies market? Ans: Growing incidence of blood cancer and increasing focus on the development of new treatments are expected to drive the market.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Hematologic Malignancies Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Hematologic Malignancies Market 3.4. Geographical Snapshot of the Hematologic Malignancies Market, By Manufacturer share 4. Hematologic Malignancies Market Overview, 2020-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Hematologic Malignancies Market 5. Supply Side and Demand Side Indicators 6. Hematologic Malignancies Market Analysis and Forecast, 2020-2027 6.1. Hematologic Malignancies Market Size & Y-o-Y Growth Analysis. 7. Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 7.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 7.1.1. Leukemia 7.1.1.1. Acute Lymphocytic Leukemia 7.1.1.2. Chronic Lymphocytic Leukemia 7.1.1.3. Acute Myeloid Leukemia 7.1.1.4. Chronic Myeloid Leukemia 7.1.2. Lymphoma 7.1.3. Multiple Myeloma 7.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 7.2.1. Chemotherapy 7.2.2. Radiotherapy 7.2.3. Immunotherapy 7.2.4. Stem Cell Transplantation 7.2.5. Others 8. Hematologic Malignancies Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2020-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 9.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 9.1.1. Leukemia 9.1.1.1. Acute Lymphocytic Leukemia 9.1.1.2. Chronic Lymphocytic Leukemia 9.1.1.3. Acute Myeloid Leukemia 9.1.1.4. Chronic Myeloid Leukemia 9.1.2. Lymphoma 9.1.3. Multiple Myeloma 9.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 9.2.1. Chemotherapy 9.2.2. Radiotherapy 9.2.3. Immunotherapy 9.2.4. Stem Cell Transplantation 9.2.5. Others 10. North America Hematologic Malignancies Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 11.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 11.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 12. Canada Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 12.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 12.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 13. Mexico Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 13.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 13.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 14. Europe Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 14.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 14.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 15. Europe Hematologic Malignancies Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 16.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 16.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 17. France Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 17.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 17.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 18. Germany Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 18.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 18.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 19. Italy Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 19.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 19.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 20. Spain Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 20.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 20.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 21. Sweden Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 21.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 21.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 22. CIS Countries Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 22.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 22.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 23. Rest of Europe Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 23.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 23.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 24. Asia Pacific Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 24.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 24.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 25. Asia Pacific Hematologic Malignancies Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 26.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 26.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 27. India Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 27.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 27.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 28. Japan Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 28.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 28.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 29. South Korea Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 29.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 29.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 30. Australia Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 30.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 30.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 31. ASEAN Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 31.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 31.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 32. Rest of Asia Pacific Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 32.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 32.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 33. Middle East Africa Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 33.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 33.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 34. Middle East Africa Hematologic Malignancies Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 35.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 35.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 36. GCC Countries Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 36.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 36.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2020-2027 37.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 37.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 38. Nigeria Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 38.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 38.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 39. Rest of ME&A Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 39.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 39.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 40. South America Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 40.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 40.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 41. South America Hematologic Malignancies Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 42.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 42.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 43. Argentina Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 43.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 43.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 44. Rest of South America Hematologic Malignancies Market Analysis and Forecasts, 2020-2027 44.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 44.2. Market Size (Value) Estimates & Forecast By Therapy, 2020-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Hematologic Malignancies Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Pfizer, Inc. 45.3.3. F. Hoffmann-LA Roche lt 45.3.4. Sanofi-Aventis 45.3.5. Bristol-Myers Squibb Company 45.3.6. AbbVie, Inc. 45.3.7. Novartis AG 45.3.8. GlaxoSmithKline PLC 45.3.9. Celgene Corporation 45.3.10. Johnson & Johnson Services, Inc 45.3.11. Takeda Pharmaceutical Company Limited 45.3.12. Sanofi 45.3.13. Novartis AG 45.3.14. AstraZeneca 45.3.15. Amgen Inc. 45.3.16. Byer AG 46. Primary Key Insights

About This Report

Report ID 124404
Category Healthcare
Published Date Oct 2021
Updated Date
Contact Us